id:"swepub:oai:DiVA.org:uu-130804"
Sökning: id:"swepub:oai:DiVA.org:uu-130804" > Safety and efficacy...
- 1 av 1
- Föregående post
- Nästa post
- Till träfflistan
- von Heideman, AnneUppsala universitet,Enheten för onkologi (författare)
Safety and efficacy of NAD depleting cancer drugs : results of a phase I clinical trial of CHS 828 and overview of published data
- Artikel/kapitelEngelska2010
Förlag, utgivningsår, omfång ...
- 2009-09-30
- Springer Science and Business Media LLC,2010
- printrdacarrier
Nummerbeteckningar
- LIBRIS-ID:oai:DiVA.org:uu-130804
- https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-130804URI
- https://doi.org/10.1007/s00280-009-1125-3DOI
Kompletterande språkuppgifter
- Språk:engelska
- Sammanfattning på:engelska
Ingår i deldatabas
- SwePubSwePub
Klassifikation
Anmärkningar
- PURPOSE: Depletion of cellular nicotinamide adenine dinucleotide (NAD) by inhibition of its synthesis is a new pharmacological principle for cancer treatment currently in early phases of clinical development. We present new and previously published data on the safety and efficacy of these drugs based on early clinical trials. METHODS: A phase I clinical trial of CHS 828 in patients with advanced solid tumours was performed. Published clinical trials on NAD depleting drugs for cancer treatment were summarised for safety and efficacy. RESULTS: Seven patients with previously treated solid tumours received oral administration of CHS 828 in the dose range 20-80 mg once weekly for 3 weeks in 4 weeks cycles. Toxicity was dominated by gastrointestinal symptoms including nausea, vomiting, diarrhoea, constipation, subileus and gastric ulcer. One patient had thrombocytopenia grade 2. There were two cases each of grade 3-4 hyperuricemia and hypokalemia. Safety and efficacy of the NAD depleting drugs CHS 828 and FK866 have been reported from four phase I clinical trials, including a total of 97 patients with previously treated solid tumours. Outstanding toxicity reported was thrombocytopenia and various gastrointestinal symptoms. No objective tumour remission has been observed in the total of 104 patients treated in the above early trials. CONCLUSIONS: Critical toxicity from NAD depleting cancer drugs to consider in future trials seems to be thrombocytopenia and various gastrointestinal symptoms. Efficacy of NAD depleting drugs when used alone is expected to be low.
Ämnesord och genrebeteckningar
- Cancer
- NAD depletion
- Phase I clinical trial
- CHS 828
- FK866
- GMX1777
- MEDICINE
- MEDICIN
Biuppslag (personer, institutioner, konferenser, titlar ...)
- Berglund, ÅkeUppsala universitet,Enheten för onkologi(Swepub:uu)akebergl (författare)
- Larsson, RolfUppsala universitet,Enheten för onkologi,Klinisk farmakologi,Cancer Pharmacology and Informatics/Rolf Larsson(Swepub:uu)rolflars (författare)
- Nygren, PeterUppsala universitet,Enheten för onkologi,Nygren(Swepub:uu)peterng (författare)
- Uppsala universitetEnheten för onkologi (creator_code:org_t)
Sammanhörande titlar
- Ingår i:Cancer Chemotherapy and Pharmacology: Springer Science and Business Media LLC65:6, s. 1165-11720344-57041432-0843
Internetlänk
Hitta via bibliotek
- Cancer Chemotherapy and Pharmacology (Sök värdpublikationen i LIBRIS)
Till lärosätets databas
- 1 av 1
- Föregående post
- Nästa post
- Till träfflistan
Hitta mer i SwePub
- Av författaren/redakt...
- von Heideman, An ...
- Berglund, Åke
- Larsson, Rolf
- Nygren, Peter
- Artiklar i publikationen
- Cancer Chemother ...
- Av lärosätet
- Uppsala universitet
Sök utanför SwePub
- Sök vidare i:
- Google Book Search
- Google Scholar
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.
- Copyright © LIBRIS - Nationella bibliotekssystem
- LIBRIS.kb.se
